MARKET

CMPX

CMPX

Compass Therapeutics Inc
NASDAQ
1.100
-0.010
-0.90%
After Hours: 1.100 0 0.00% 16:01 06/21 EDT
OPEN
1.110
PREV CLOSE
1.110
HIGH
1.150
LOW
1.090
VOLUME
503.26K
TURNOVER
0
52 WEEK HIGH
3.450
52 WEEK LOW
1.060
MARKET CAP
151.35M
P/E (TTM)
-3.1312
1D
5D
1M
3M
1Y
5Y
Compass Therapeutics: Pointing Right At Some Tough Cancers
Seeking Alpha · 2d ago
Weekly Report: what happened at CMPX last week (0610-0614)?
Weekly Report · 5d ago
12 Health Care Stocks Moving In Monday's After-Market Session
Entero Therapeutics (NASDAQ:ENTO) stock rose 10.2% to $2.6 during Monday's after-market session. LifeMD stock rose 5.81% in the same period. Losers Vicarious Surgical (NYSE:RBOT) and ProKidney stock fell 15.6% during the session.
Benzinga · 06/10 20:31
Weekly Report: what happened at CMPX last week (0603-0607)?
Weekly Report · 06/10 10:46
Compass Therapeutics Price Target Maintained With a $10.00/Share by HC Wainwright & Co.
Dow Jones · 06/03 11:10
HC Wainwright & Co. Reiterates Buy on Compass Therapeutics, Maintains $10 Price Target
Benzinga · 06/03 11:00
Weekly Report: what happened at CMPX last week (0527-0531)?
Weekly Report · 06/03 10:48
Analysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX), Compass Therapeutics (CMPX) and Kymera Therapeutics (KYMR)
TipRanks · 06/03 10:30
More
About CMPX
Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is developing proprietary antibody-based therapeutics to treat multiple human diseases. Its pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. Its lead product candidate, CTX-009, is a bispecific antibody targeting Delta-like ligand 4 (DLL4), a ligand of Notch-1, and vascular endothelial growth factor A (VEGF-A). Its second program, CTX-471, is an agonistic antibody targeting a member of the tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD-137, a co-stimulatory receptor which is mostly expressed on activated, but not on resting T-cells and NK cells. Its third program, CTX-8371, is a bispecific antibody targeting the programmed cell death protein-1 (PD-1), an inhibitory immune checkpoint receptor and its ligand PD-L1, two validated immune-oncology targets.

Webull offers Compass Therapeutics Inc. stock information, including NASDAQ: CMPX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CMPX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CMPX stock methods without spending real money on the virtual paper trading platform.